Prof. Molly Stevens receives the Novo Nordisk Prize – Understanding how materials and biology interact has revolutionised healthcare technologies

/in

Science of small things does not sound like something that can have a big impact on the world, but nanotechnology has proved this is wrong. Tissue engineering, efficient drug delivery and more sensitive screening for diseases are just a few examples. According to Professor Molly Stevens, the new technologies can democratise access to healthcare. She […]

Read more

Novo Holdings participates in Hemab Therapeutics $135M Series B Financing

/in

Hemab Therapeutics is a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders Funding enables completion of ongoing Phase 1/2 study of bispecific antibody HMB-001 in Glanzmann Thrombasthenia, initiation of pivotal studies, start and conclusion of Phase 1/2 study of HMB-VWF in von Willebrand Disease, as well as future […]

Read more

Methinks receives CE Marked Certification for AI-based stroke triage software

/in

Methinks Stroke Suite is a disruptive technology that has the potential to provide early, automated detection of large vessel occlusions, both hyperdense and not, from non-contrast computed tomographies BARCELONA, February 21, 2023 – Methinks, a digital health Company that specializes in early detection and management of Acute Stroke (AS), using artificial intelligence (AI), today announced […]

Read more

Zephyrus Innovations announces US FDA approval for its Aeroject™ 3ml safety syringe

/in

Aeroject™ 3ml safety syringe is a single-use, affordable, first generation syringe Aeroject™ has a permanently attached needle system, which upon retraction, fully encases the needle, preventing needle reuse and accidental needlestick The ultra-low wasted space syringes allow for the maximum number of doses to be administered per vial, lowering costs 16 February 2023 – Vancouver, Canada: […]

Read more

Leucid Bio provides business update and outlook for 2023

/in

Proprietary Lateral CAR Platform achieved pre-clinical proof-of-concept data demonstrating prolonged disease-free survival compared to other CAR T-cell products. Lead programme, LEU011 has completed pre-clinical development for the treatment of solid tumours and is in pre-clinical development for a range of haematological malignancies. Leucid expects to file its CTA to initiate the clinical trial in H1 […]

Read more